Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)

Organon

Status: Completed

Conditions: Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT01368185

MK-0954A-366

0954A-366

Details and patient eligibility

About

This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid levels.

Enrollment: 1,705 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant was >20 years and <75 years of age on the index date (i.e., the date of initiating MK-0954A therapy)

• Diagnosed with hypertension and had received MK-0954A 50/12.5 mg for at least 3 months

• Had at least one serum uric acid measurements at baseline and one at 3 months after using MK-0954A 50/12.5 mg

• Had the following records documented in the chart during the data collection period:

  • medical history and co-morbidities (if available)
  • sitting blood pressure, serum uric acid, lipid profile test results before and after using MK-0954A 50/12.5 mg
  • serum electrolytes, serum creatinine, and pre-meal sugar (if available)
  • prescription information of all antihypertensive regimens

Exclusion criteria

• Had been treated with diuretic or angiotensin-receptor blockers (ARBs) 2 weeks before initiated treatment with MK-0954A 50/12.5 mg
• Serum creatinine >2 mg/dL

Trial design

1,705 participants in 1 patient group

All Participants

Description:

Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months